The Good Virus.
Replimune is expanding their pipeline of tumor-derived oncolytic immunotherapies (TDOI) designed to change the landscape of cancer for good.
“The Good virus” moa video
With a tumor-ridden microenvironment as our setting, we tell the story of RP1, a smart and determined predator designed to destroy cancer at the source, while empowering a targeted immune response that will bring harmony back into the patient’s world.
ROLE
Creative Director
Visual Designer
AGENCY
Broth
CLIENT
Replimune
DELIVERABLES
MOA video
Congress booths
iDetail
Social ads
OI in the Wild
The final style of this MOA video was inspired by a nature documentary in both the cinematographic approach and voice-over style. We partnered with Lightfarm, who collaborated every step of the way—from color scheme and textures to sound effects and lighting—to produce a beautiful microscopic, high-stakes documentary.
OI=oncolytic immunotherapy.
Rebranding “virus” in a post-COVID world
We were tasked to create an MOA video that could change the negative perception of viruses by explaining how a virus-based, cancer-fighting drug can be reimagined for good.
The content and tone were especially important to consider, as this video would be seen by oncology specialists and patients or caregivers researching new cancer treatments.
At the end of the day, “The Good Virus” features an oncolytic immunotherapy that represents an exciting new frontier in cancer therapy everyone can get behind.
